Access the full text.
Sign up today, get DeepDyve free for 14 days.
Robert Ferris, G. Blumenschein, J. Fayette, J. Guigay, A. Colevas, L. Licitra, K. Harrington, S. Kasper, E. Vokes, C. Even, F. Worden, Nabil Saba, L. Docampo, R. Haddad, T. Rordorf, N. Kiyota, M. Tahara, M. Monga, M. Lynch, W. Geese, J. Kopit, James Shaw, Maura Gillison (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.The New England journal of medicine, 375 19
L. Schnipper, R. Schilsky (2017)
Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs?JAMA oncology, 4 3
O. Ben-Aharon, R. Magnezi, M. Leshno, D. Goldstein (2017)
Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer CareJAMA Oncology, 4
A. Vivot, A. Vivot, J. Jacot, J. Jacot, J. Zeitoun, J. Zeitoun, Philippe Ravaud, P. Créquit, P. Créquit, Raphaël Porcher, Raphaël Porcher, Raphaël Porcher (2017)
Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015Annals of Oncology, 28
L. Schnipper, N. Davidson, D. Wollins, D. Blayney, A. Dicker, P. Ganz, J. Hoverman, R. Langdon, G. Lyman, N. Meropol, T. Mulvey, L. Newcomer, J. Peppercorn, B. Polite, D. Raghavan, G. Rossi, L. Saltz, D. Schrag, Thomas Smith, P. Yu, C. Hudis, J. Vose, R. Schilsky (2016)
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 24
Letters Stephen G. Chun, MD 5-year overall survival ; consequently, it is also accredited Todd A. Pezzi, MD, MBA grade A for curative potential and the final ESMO-MCBS v1.1 David L. Schwartz, MD score is recorded as both A and 4. We welcome further external review of the capacity of Author Affiliations: Division of Radiation Oncology, University of Texas MD ESMO-MCBS v1.1 to evaluate immunotherapy trials, and we Anderson Cancer Center, Houston (Chun, Pezzi, Schwartz); Department of hope that Ben-Aharon and colleagues will undertake this Radiation Oncology, University of Tennessee Health Science Center, Memphis challenge. (Schwartz). Corresponding Author: Stephen G. Chun, MD, Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Nathan I. Cherny, MBBS, FRACP, FRCP, LLD TX 77030 (sgchun@mdanderson.org). Elisabeth G. E. de Vries, MD, PhD Published Online: August 2, 2018. doi:10.1001/jamaoncol.2018.3292 For the European Society for Medical Oncology Magnitude Conflict of Interest Disclosures: None reported. of Clinical Benefit Scale Working Group 1. Pezzi TA, Schwartz DL, Mohamed ASR, et al. Barriers to combined-modality therapy for limited-stage small cell lung cancer [published online January 4, Author Affiliations: Cancer Pain and Palliative Medicine Service, Department of 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2017.4504 Medical Oncology,
JAMA Oncology – American Medical Association
Published: Oct 16, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.